http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 25 Aug 2026 06:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/PRNewswire/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/PRNewswire/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405